Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.

Also called NCT06168994

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06168994
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT06168994. Randomized; single masking; primary purpose prevention. Start 2024-02-01 (anticipated); primary completion 2026-09-29 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease
Condition
Paroxysmal Atrial Fibrillation
Intervention (Drug)
Eplerenone
Lead sponsor
Assiut University (class: other)

Record details

Record id
cardio:ct-nct06168994
Content hash
9149c8606aea342ea288575e4305f520aca2175737eead3340efb5163401dfc6